2. Search Result
Search Result
Results for "

VEGF-IN-1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99215
    Parsatuzumab

    Anti-EGFL7; RG 7414

    		 VEGFR Cancer
    Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
    Parsatuzumab
  • HY-136477
    Pentagamavunon-1

    PGV-1

    		 Apoptosis COX VEGFR NF-κB Cancer
    Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). PGV-1 inhibits NF-κB activation [1].
    Pentagamavunon-1
  • HY-P9951A
    Ranibizumab (anti-VEGF)

    RG-6321 (anti-VEGF)

    		 VEGFR Cardiovascular Disease
    Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research [1].
    Ranibizumab (anti-VEGF)
  • HY-137941
    Roxatidine

    		Histamine Receptor Caspase NF-κB p38 MAPK Inflammation/Immunology
    Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is an orally active histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect. Roxatidine is promising for research of gastric and duodenal ulcers [1] .
    Roxatidine
  • HY-19306
    SB-267268

    		Integrin Cancer
    SB-267268 is a selective and nonpeptidic alpha(v)beta3 (αvβ3) and alpha(v)beta5 (αvβ5) integrins antagonist, with Kis of 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respectively. SB-267268 inhibits human and mouse αvβ3 with IC50s of 0.68 and 0.29 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression .
    SB-267268
  • HY-168279
    VEGF-IN-1

    		VEGFR Cancer
    VEGF-IN-1 (compound 6) can reduce the release of VEGF in U87-MG cells and inhibit angiogenesis in vitro. VEGF-IN-1 can inhibit cell proliferation by inducing autophagy in tumor cells, with an IC50 value of 28.35 μM for U87-MG cells [1].
    VEGF-IN-1
  • HY-119112A
    LY 379196

    		PKC Neurological Disease
    LY 379196 is a PKC-β inhibitor (IC50: 50 nM and 30 nM for PKC βI and βII respectively). LY 379196 inhibits the VEGF, IGF-1 and bFGF-induced proliferation of bovine retinal microvascular endothelial cells (BREC). LY 379196 is an antiproliferatory agentfor proliferative retinopathy [1] .
    LY 379196
  • HY-148316
    hVEGF-IN-2

    		VEGFR Cancer
    hVEGF-IN-2 (compound 19) is a selective VEGF (Flk-1) receptor tyrosine kinases (RTK) inhibitor with an IC50 value of 2.5 μM. hVEGF-IN-2 inhibits PDGF RTK activity with an IC50 value of 33.1 μM. hVEGF-IN-2 can be used for the development of RTK-specific agents [1].
    hVEGF-IN-2
  • HY-137941R
    Roxatidine (Standard)

    		Histamine Receptor Inflammation/Immunology
    Roxatidine (Standard) is the analytical standard of Roxatidine. This product is intended for research and analytical applications. Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is a histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect [1].
    Roxatidine (Standard)
  • HY-18187
    Ki 23057

    		Apoptosis Cancer
    Ki 23057 is a competitive, orally active inhibitor for tyrosine kinase, which inhibits the phosphorylation of K-samII/FGF-R2, VEGF-R1, VEGF-R2, PDGF-Rβ and c-Kit, with IC50s of 88, 69, 83, 100 and 480 nM. Ki 23057 inhibits the proliferation of sclerogastric cancer cells OCUM-2MD3 and OCUM-8, and induces apoptosis. Ki 23057 exhibits antitumor efficacy in mouse models [1].
    Ki 23057

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: